STTR Phase I:High Pressure Disaggregation of IVIg Formulations For Increased Yield and Safety

STTR 第一阶段：IVIG 制剂的高压分解以提高产量和安全性

• 批准号: 0420061
• 负责人: Lyndal Hesterberg
• 金额: $ 9.82万
• 依托单位: BaroFold, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0420061&HistoricalAwards=false
• 关键词: STTR; Phase; Pressure; Disaggregation; IVIg

This Small Business Technology Transfer Research (STTR) Phase I project proposes to use high pressures for disaggregation and proper refolding of aggregated proteins in commercial IVIg (immunoglobins for intravenous administration) formulations. The commercial application of this project will be in improved quality of therapeutic proteins for intravenous administration. Increased process yields will lower patient costs for IVIg therapies, and IVIg formulations with dramatically diminished aggregate content will lower side effects and reduce the risk of severe complications.

这个小企业技术转让研究（STTR）第一阶段项目提出使用高压解聚和正确的商业IVIg（静脉注射免疫球蛋白）制剂中的聚集蛋白质的重折叠。该项目的商业应用将是提高静脉给药的治疗性蛋白质的质量。 增加的工艺产量将降低IVIg治疗的患者成本，并且具有显著减少的聚集体含量的IVIg制剂将降低副作用并降低严重并发症的风险。